AbbVie Inc. Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax
AbbVie Inc. (ABBV) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax of -$2.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax · last filed 2026-08-03
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2026-06-30 was -$2.00M, a 106.06% decline year-over-year.
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2026-03-31 was -$5.00M, a 129.41% decline year-over-year.
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-12-31 was $15.00M.
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-09-30 was -$2.00M, a 108.00% decline year-over-year.
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2025 was $63.00M.
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2024 was -$39.00M, a 360.00% decline from fiscal 2023.
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2023 was $15.00M.
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2022 was -$10.00M.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 6 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 9 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.00M 10-Q · filed 2026-08-03 | -$7.00M 10-Q · filed 2026-08-03 | $8.00M derived: sum of 3 quarters · filed 2026-08-03 | $6.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$5.00M 10-Q · filed 2026-05-08 | $10.00M derived: sum of 2 quarters · filed 2026-05-08 | $8.00M derived: sum of 3 quarters · filed 2026-05-08 | $41.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $13.00M derived: sum of 2 quarters · filed 2026-02-20 | $46.00M derived: sum of 3 quarters · filed 2026-08-03 | $63.00M 10-K · filed 2026-02-20 |
| 2025-09-30 | -$2.00M 10-Q · filed 2025-11-04 | $31.00M derived: sum of 2 quarters · filed 2026-08-03 | $48.00M 10-Q · filed 2025-11-04 | $8.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $33.00M 10-Q · filed 2026-08-03 | $50.00M 10-Q · filed 2026-08-03 | $10.00M derived: sum of 3 quarters · filed 2026-08-03 | $35.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $17.00M 10-Q · filed 2026-05-08 | -$23.00M derived: sum of 2 quarters · filed 2026-05-08 | $2.00M derived: sum of 3 quarters · filed 2026-05-08 | -$2.00M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$15.00M derived: sum of 2 quarters · filed 2026-02-20 | -$19.00M derived: sum of 3 quarters · filed 2026-02-20 | -$39.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | $25.00M 10-Q · filed 2025-11-04 | $21.00M derived: sum of 2 quarters · filed 2025-11-04 | $1.00M 10-Q · filed 2025-11-04 | $27.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | -$4.00M 10-Q · filed 2025-08-04 | -$24.00M 10-Q · filed 2025-08-04 | $2.00M derived: sum of 3 quarters · filed 2026-02-20 | -$15.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | -$20.00M 10-Q · filed 2025-05-09 | $6.00M derived: sum of 2 quarters · filed 2026-02-20 | -$11.00M derived: sum of 3 quarters · filed 2026-02-20 | -$17.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $26.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $9.00M derived: sum of 2 quarters · filed 2026-02-20 | $3.00M derived: sum of 3 quarters · filed 2026-02-20 | $15.00M 10-K · filed 2026-02-20 |
| 2023-09-30 | -$17.00M 10-Q · filed 2024-11-04 | -$23.00M derived: sum of 2 quarters · filed 2024-11-04 | -$11.00M 10-Q · filed 2024-11-04 | $9.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | -$6.00M 10-Q · filed 2024-08-07 | $6.00M 10-Q · filed 2024-08-07 | $26.00M derived: sum of 3 quarters · filed 2025-02-14 | $15.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $12.00M 10-Q · filed 2024-05-03 | $32.00M derived: sum of 2 quarters · filed 2025-02-14 | $21.00M derived: sum of 3 quarters · filed 2025-02-14 | $9.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $9.00M derived: sum of 2 quarters · filed 2025-02-14 | -$3.00M derived: sum of 3 quarters · filed 2025-02-14 | -$10.00M 10-K · filed 2025-02-14 |
| 2022-09-30 | -$11.00M 10-Q · filed 2023-11-06 | -$23.00M derived: sum of 2 quarters · filed 2023-11-06 | -$30.00M 10-Q · filed 2023-11-06 | -$33.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$12.00M 10-Q · filed 2023-08-07 | -$19.00M 10-Q · filed 2023-08-07 | -$22.00M derived: sum of 3 quarters · filed 2024-02-20 | -$30.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$7.00M 10-Q · filed 2023-05-05 | -$10.00M derived: sum of 2 quarters · filed 2024-02-20 | -$18.00M derived: sum of 3 quarters · filed 2024-02-20 | -$17.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | -$3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$11.00M derived: sum of 2 quarters · filed 2024-02-20 | -$10.00M derived: sum of 3 quarters · filed 2024-02-20 | -$35.00M 10-K · filed 2024-02-20 |
| 2021-09-30 | -$8.00M 10-Q · filed 2022-11-04 | -$7.00M derived: sum of 2 quarters · filed 2022-11-04 | -$32.00M 10-Q · filed 2022-11-04 | -$15.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $1.00M 10-Q · filed 2022-08-04 | -$24.00M 10-Q · filed 2022-08-04 | -$7.00M derived: sum of 3 quarters · filed 2023-02-17 | $8.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | -$25.00M 10-Q · filed 2022-05-06 | -$8.00M derived: sum of 2 quarters · filed 2023-02-17 | $7.00M derived: sum of 3 quarters · filed 2023-02-17 | $11.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $32.00M derived: sum of 2 quarters · filed 2023-02-17 | $36.00M derived: sum of 3 quarters · filed 2023-02-17 | $28.00M 10-K · filed 2023-02-17 |
| 2020-09-30 | $15.00M 10-Q · filed 2021-11-02 | $19.00M derived: sum of 2 quarters · filed 2021-11-02 | $11.00M 10-Q · filed 2021-11-02 | $17.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | $4.00M 10-Q · filed 2021-08-02 | -$4.00M 10-Q · filed 2021-08-02 | $2.00M derived: sum of 3 quarters · filed 2022-02-18 | -$14.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | -$8.00M 10-Q · filed 2021-05-07 | -$2.00M derived: sum of 2 quarters · filed 2022-02-18 | -$18.00M derived: sum of 3 quarters · filed 2022-02-18 | -$13.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | -$10.00M derived: sum of 2 quarters · filed 2022-02-18 | -$5.00M derived: sum of 3 quarters · filed 2022-02-18 | -$4.00M 10-K · filed 2022-02-18 |
| 2019-09-30 | -$16.00M 10-Q · filed 2020-11-04 | -$11.00M derived: sum of 2 quarters · filed 2020-11-04 | -$10.00M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $5.00M 10-Q · filed 2020-08-04 | $6.00M 10-Q · filed 2020-08-04 | ||
| 2018-12-31 | -$18.00M 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |